ID   NLK_HUMAN               Reviewed;         527 AA.
AC   Q9UBE8; B2RCX1; Q2PNI9; Q6P2A3;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   03-NOV-2009, sequence version 2.
DT   10-MAY-2017, entry version 160.
DE   RecName: Full=Serine/threonine-protein kinase NLK;
DE            EC=2.7.11.24;
DE   AltName: Full=Nemo-like kinase;
DE   AltName: Full=Protein LAK1;
GN   Name=NLK; Synonyms=LAK1 {ECO:0000312|EMBL:AAD56013.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000312|EMBL:AAF04857.1}
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta {ECO:0000269|PubMed:10863097};
RX   PubMed=10863097; DOI=10.1016/S0378-1119(00)00188-8;
RA   Kehrer-Sawatzki H., Moschgath E., Maier C., Legius E., Elgar G.,
RA   Krone W.;
RT   "Characterization of the Fugu rubripes NLK and FN5 genes flanking the
RT   NF1 (Neurofibromatosis type 1) gene in the 5' direction and mapping of
RT   the human counterparts.";
RL   Gene 251:63-71(2000).
RN   [2] {ECO:0000312|EMBL:AAD56013.1}
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=T-cell;
RA   Wang C., Lo H.;
RT   "Cloning of human LAK1 cDNA.";
RL   Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Amygdala;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4] {ECO:0000312|EMBL:AAD56013.1}
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, AND ENZYME REGULATION.
RX   PubMed=12482967; DOI=10.1128/MCB.23.1.131-139.2003;
RA   Ishitani T., Kishida S., Hyodo-Miura J., Ueno N., Yasuda J.,
RA   Waterman M., Shibuya H., Moon R.T., Ninomiya-Tsuji J., Matsumoto K.;
RT   "The TAK1-NLK mitogen-activated protein kinase cascade functions in
RT   the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling.";
RL   Mol. Cell. Biol. 23:131-139(2003).
RN   [7]
RP   FUNCTION, AND ENZYME REGULATION.
RX   PubMed=15004007; DOI=10.1101/gad.1166904;
RA   Ohkawara B., Shirakabe K., Hyodo-Miura J., Matsuo R., Ueno N.,
RA   Matsumoto K., Shibuya H.;
RT   "Role of the TAK1-NLK-STAT3 pathway in TGF-beta-mediated mesoderm
RT   induction.";
RL   Genes Dev. 18:381-386(2004).
RN   [8] {ECO:0000305}
RP   INTERACTION WITH MYB AND HIPK2.
RX   PubMed=15082531; DOI=10.1101/gad.1170604;
RA   Kanei-Ishii C., Ninomiya-Tsuji J., Tanikawa J., Nomura T.,
RA   Ishitani T., Kishida S., Kokura K., Kurahashi T., Ichikawa-Iwata E.,
RA   Kim Y., Matsumoto K., Ishii S.;
RT   "Wnt-1 signal induces phosphorylation and degradation of c-Myb protein
RT   via TAK1, HIPK2, and NLK.";
RL   Genes Dev. 18:816-829(2004).
RN   [9]
RP   FUNCTION.
RX   PubMed=14960582; DOI=10.1074/jbc.M307801200;
RA   Smit L., Baas A., Kuipers J., Korswagen H., van de Wetering M.,
RA   Clevers H.;
RT   "Wnt activates the Tak1/Nemo-like kinase pathway.";
RL   J. Biol. Chem. 279:17232-17240(2004).
RN   [10]
RP   FUNCTION, AUTOPHOSPHORYLATION, INTERACTION WITH MAP3K7 AND STAT3, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=15764709; DOI=10.1073/pnas.0500679102;
RA   Kojima H., Sasaki T., Ishitani T., Iemura S., Zhao H., Kaneko S.,
RA   Kunimoto H., Natsume T., Matsumoto K., Nakajima K.;
RT   "STAT3 regulates Nemo-like kinase by mediating its interaction with
RT   IL-6-stimulated TGFbeta-activated kinase 1 for STAT3 Ser-727
RT   phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:4524-4529(2005).
RN   [11]
RP   INTERACTION WITH RNF138 AND TCF7L2.
RX   PubMed=16714285; DOI=10.1074/jbc.M602089200;
RA   Yamada M., Ohnishi J., Ohkawara B., Iemura S., Satoh K.,
RA   Hyodo-Miura J., Kawachi K., Natsume T., Shibuya H.;
RT   "NARF, an nemo-like kinase (NLK)-associated ring finger protein
RT   regulates the ubiquitylation and degradation of T cell factor/lymphoid
RT   enhancer factor (TCF/LEF).";
RL   J. Biol. Chem. 281:20749-20760(2006).
RN   [12]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH CHD7; PPARG AND SETDB1,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-167.
RX   PubMed=17952062; DOI=10.1038/ncb1647;
RA   Takada I., Mihara M., Suzawa M., Ohtake F., Kobayashi S., Igarashi M.,
RA   Youn M.Y., Takeyama K., Nakamura T., Mezaki Y., Takezawa S.,
RA   Yogiashi Y., Kitagawa H., Yamada G., Takada S., Minami Y., Shibuya H.,
RA   Matsumoto K., Kato S.;
RT   "A histone lysine methyltransferase activated by non-canonical Wnt
RT   signalling suppresses PPAR-gamma transactivation.";
RL   Nat. Cell Biol. 9:1273-1285(2007).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-298 AND SER-522, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-298, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   FUNCTION, INTERACTION WITH FOXO1, AND MUTAGENESIS OF LYS-167.
RX   PubMed=20061393; DOI=10.1074/jbc.M110.101824;
RA   Kim S., Kim Y., Lee J., Chung J.;
RT   "Regulation of FOXO1 by TAK1-Nemo-like kinase pathway.";
RL   J. Biol. Chem. 285:8122-8129(2010).
RN   [16]
RP   FUNCTION, AND INTERACTION WITH NOTCH1.
RX   PubMed=20118921; DOI=10.1038/ncb2028;
RA   Ishitani T., Hirao T., Suzuki M., Isoda M., Ishitani S., Harigaya K.,
RA   Kitagawa M., Matsumoto K., Itoh M.;
RT   "Nemo-like kinase suppresses Notch signalling by interfering with
RT   formation of the Notch active transcriptional complex.";
RL   Nat. Cell Biol. 12:278-285(2010).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH FOXO1; FOXO3 AND FOXO4.
RX   PubMed=20874444; DOI=10.1089/ars.2010.3243;
RA   Szypowska A.A., de Ruiter H., Meijer L.A.T., Smits L.M.M.,
RA   Burgering B.M.T.;
RT   "Oxidative stress-dependent regulation of Forkhead box O4 activity by
RT   nemo-like kinase.";
RL   Antioxid. Redox Signal. 14:563-578(2011).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH DAPK3 AND TCF7L2.
RX   PubMed=21454679; DOI=10.1074/jbc.M110.189829;
RA   Togi S., Ikeda O., Kamitani S., Nakasuji M., Sekine Y., Muromoto R.,
RA   Nanbo A., Oritani K., Kawai T., Akira S., Matsuda T.;
RT   "Zipper-interacting protein kinase (ZIPK) modulates canonical
RT   Wnt/beta-catenin signaling through interaction with Nemo-like kinase
RT   and T-cell factor 4 (NLK/TCF4).";
RL   J. Biol. Chem. 286:19170-19177(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-298, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   FUNCTION, AND INTERACTION WITH ATF5.
RX   PubMed=25512613; DOI=10.1128/MCB.01228-14;
RA   Zhang Z.Y., Li S.Z., Zhang H.H., Wu Q.R., Gong J., Liang T., Gao L.,
RA   Xing N.N., Liu W.B., Du R.L., Zhang X.D.;
RT   "Stabilization of ATF5 by TAK1-Nemo-like kinase critically regulates
RT   the interleukin-1beta-stimulated C/EBP signaling pathway.";
RL   Mol. Cell. Biol. 35:778-788(2015).
RN   [21]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-343.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that regulates a number
CC       of transcription factors with key roles in cell fate
CC       determination. Positive effector of the non-canonical Wnt
CC       signaling pathway, acting downstream of WNT5A, MAP3K7/TAK1 and
CC       HIPK2. Activation of this pathway causes binding to and
CC       phosphorylation of the histone methyltransferase SETDB1. The NLK-
CC       SETDB1 complex subsequently interacts with PPARG, leading to
CC       methylation of PPARG target promoters at histone H3K9 and
CC       transcriptional silencing. The resulting loss of PPARG target gene
CC       transcription inhibits adipogenesis and promotes
CC       osteoblastogenesis in mesenchymal stem cells (MSCs). Negative
CC       regulator of the canonical Wnt/beta-catenin signaling pathway.
CC       Binds to and phosphorylates TCF7L2/TCF4 and LEF1, promoting the
CC       dissociation of the TCF7L2/LEF1/beta-catenin complex from DNA, as
CC       well as the ubiquitination and subsequent proteolysis of LEF1.
CC       Together these effects inhibit the transcriptional activation of
CC       canonical Wnt/beta-catenin target genes. Negative regulator of the
CC       Notch signaling pathway. Binds to and phosphorylates NOTCH1,
CC       thereby preventing the formation of a transcriptionally active
CC       ternary complex of NOTCH1, RBPJ/RBPSUH and MAML1. Negative
CC       regulator of the MYB family of transcription factors.
CC       Phosphorylation of MYB leads to its subsequent proteolysis while
CC       phosphorylation of MYBL1 and MYBL2 inhibits their interaction with
CC       the coactivator CREBBP. Other transcription factors may also be
CC       inhibited by direct phosphorylation of CREBBP itself. Acts
CC       downstream of IL6 and MAP3K7/TAK1 to phosphorylate STAT3, which is
CC       in turn required for activation of NLK by MAP3K7/TAK1. Upon IL1B
CC       stimulus, cooperates with ATF5 to activate the transactivation
CC       activity of C/EBP subfamily members. Phosphorylates ATF5 but also
CC       stabilizes ATF5 protein levels in a kinase-independent manner
CC       (PubMed:25512613). {ECO:0000250|UniProtKB:O54949,
CC       ECO:0000269|PubMed:12482967, ECO:0000269|PubMed:14960582,
CC       ECO:0000269|PubMed:15004007, ECO:0000269|PubMed:15764709,
CC       ECO:0000269|PubMed:17952062, ECO:0000269|PubMed:20061393,
CC       ECO:0000269|PubMed:20118921, ECO:0000269|PubMed:20874444,
CC       ECO:0000269|PubMed:21454679, ECO:0000269|PubMed:25512613}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ENZYME REGULATION: Activated by dimerization and subsequent
CC       intermolecular autophosphorylation on Thr-298 (By similarity).
CC       Activated by the non-canonical Wnt signaling pathway, in which
CC       WNT5A treatment leads to activation of MAP3K7/TAK1 and HIPK2,
CC       which subsequently phosphorylates and activates this protein.
CC       Other cytokines such as IL6 may also activate this regulatory
CC       circuit. {ECO:0000250, ECO:0000269|PubMed:12482967,
CC       ECO:0000269|PubMed:15004007}.
CC   -!- SUBUNIT: Homodimer. Homodimerization is required for
CC       intermolecular autophosphorylation, kinase activation and nuclear
CC       localization (By similarity). May interact with components of
CC       cullin-RING-based SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-
CC       protein ligase complexes (By similarity). Interacts with LEF1,
CC       MEF2A, MYBL1 and MYBL2 (By similarity). Interacts with the
CC       upstream activating kinases HIPK2 and MAP3K7/TAK1. Interaction
CC       with MAP3K7/TAK1 seems to be indirect, and may be mediated by
CC       other proteins such as STAT3, TAB1 and TAB2. Interacts with and
CC       phosphorylates a number of transcription factors including FOXO1,
CC       FOXO3, FOXO4, MYB, NOTCH1 and TCF7L2/TCF4. Interacts with
CC       DAPK3/ZIPK, and this interaction may disrupt interaction with
CC       transcription factors such as TCF7L2/TCF4. Forms a transcriptional
CC       repressor complex with CHD7, PPARG and SETDB1. Interacts with
CC       RNF138/NARF. Interacts with ATF5; the interaction stabilizes ATF5
CC       at the protein level in a kinase-independent manner
CC       (PubMed:25512613). {ECO:0000250, ECO:0000269|PubMed:15082531,
CC       ECO:0000269|PubMed:15764709, ECO:0000269|PubMed:16714285,
CC       ECO:0000269|PubMed:17952062, ECO:0000269|PubMed:20061393,
CC       ECO:0000269|PubMed:20118921, ECO:0000269|PubMed:20874444,
CC       ECO:0000269|PubMed:21454679, ECO:0000269|PubMed:25512613}.
CC   -!- INTERACTION:
CC       P28799:GRN; NbExp=6; IntAct=EBI-366978, EBI-747754;
CC       Q9BYR5:KRTAP4-2; NbExp=3; IntAct=EBI-366978, EBI-10172511;
CC       Q6L8G9:KRTAP5-6; NbExp=3; IntAct=EBI-366978, EBI-10250562;
CC       P26371:KRTAP5-9; NbExp=3; IntAct=EBI-366978, EBI-3958099;
CC       O43318:MAP3K7; NbExp=3; IntAct=EBI-366978, EBI-358684;
CC       Q2TAL8:QRICH1; NbExp=3; IntAct=EBI-366978, EBI-2798044;
CC       Q96PM5:RCHY1; NbExp=5; IntAct=EBI-366978, EBI-947779;
CC       Q13485:SMAD4; NbExp=6; IntAct=EBI-366978, EBI-347263;
CC       Q14186:TFDP1; NbExp=2; IntAct=EBI-366978, EBI-749713;
CC       Q9H4I2:ZHX3; NbExp=4; IntAct=EBI-366978, EBI-948582;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}. Cytoplasm
CC       {ECO:0000250}. Note=Predominantly nuclear. A smaller fraction is
CC       cytoplasmic (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: Contains a TQE activation loop motif in which
CC       autophosphorylation of the threonine residue (Thr-298) is
CC       sufficient for kinase activation. This mode of activation
CC       contrasts with that of classical MAP kinases, which contain a TXY
CC       activation loop motif in which phosphorylation of both the
CC       threonine and tyrosine residues is required for kinase activation.
CC   -!- PTM: Phosphorylated on Thr-298. Intermolecular autophosphorylation
CC       on Thr-298 activates the enzyme.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. MAP kinase subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD56013.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAF04857.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=ABC40748.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAG37718.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF197898; AAF04857.1; ALT_INIT; mRNA.
DR   EMBL; AF180819; AAD56013.1; ALT_INIT; mRNA.
DR   EMBL; AK315315; BAG37718.1; ALT_INIT; mRNA.
DR   EMBL; DQ316259; ABC40748.1; ALT_INIT; Genomic_DNA.
DR   EMBL; BC064663; AAH64663.2; -; mRNA.
DR   CCDS; CCDS11224.2; -.
DR   RefSeq; NP_057315.3; NM_016231.4.
DR   UniGene; Hs.208759; -.
DR   ProteinModelPortal; Q9UBE8; -.
DR   SMR; Q9UBE8; -.
DR   BioGrid; 119685; 56.
DR   IntAct; Q9UBE8; 39.
DR   MINT; MINT-2873487; -.
DR   STRING; 9606.ENSP00000384625; -.
DR   BindingDB; Q9UBE8; -.
DR   ChEMBL; CHEMBL5364; -.
DR   GuidetoPHARMACOLOGY; 2125; -.
DR   iPTMnet; Q9UBE8; -.
DR   PhosphoSitePlus; Q9UBE8; -.
DR   BioMuta; NLK; -.
DR   DMDM; 262527551; -.
DR   EPD; Q9UBE8; -.
DR   PaxDb; Q9UBE8; -.
DR   PeptideAtlas; Q9UBE8; -.
DR   PRIDE; Q9UBE8; -.
DR   Ensembl; ENST00000407008; ENSP00000384625; ENSG00000087095.
DR   GeneID; 51701; -.
DR   KEGG; hsa:51701; -.
DR   UCSC; uc010crj.4; human.
DR   CTD; 51701; -.
DR   DisGeNET; 51701; -.
DR   GeneCards; NLK; -.
DR   HGNC; HGNC:29858; NLK.
DR   HPA; HPA018192; -.
DR   HPA; HPA056511; -.
DR   MIM; 609476; gene.
DR   neXtProt; NX_Q9UBE8; -.
DR   OpenTargets; ENSG00000087095; -.
DR   PharmGKB; PA134914500; -.
DR   eggNOG; KOG0664; Eukaryota.
DR   eggNOG; ENOG410XRAQ; LUCA.
DR   GeneTree; ENSGT00550000074298; -.
DR   HOGENOM; HOG000233024; -.
DR   HOVERGEN; HBG014652; -.
DR   InParanoid; Q9UBE8; -.
DR   KO; K04468; -.
DR   OMA; DDGFEKN; -.
DR   OrthoDB; EOG091G05X6; -.
DR   PhylomeDB; Q9UBE8; -.
DR   TreeFam; TF315210; -.
DR   Reactome; R-HSA-4086398; Ca2+ pathway.
DR   SignaLink; Q9UBE8; -.
DR   SIGNOR; Q9UBE8; -.
DR   ChiTaRS; NLK; human.
DR   GeneWiki; NLK; -.
DR   GenomeRNAi; 51701; -.
DR   PRO; PR:Q9UBE8; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000087095; -.
DR   CleanEx; HS_NLK; -.
DR   ExpressionAtlas; Q9UBE8; baseline and differential.
DR   Genevisible; Q9UBE8; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; ISS:UniProtKB.
DR   GO; GO:0004707; F:MAP kinase activity; ISS:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome.
DR   GO; GO:0042169; F:SH2 domain binding; ISS:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; ISS:UniProtKB.
DR   GO; GO:0030178; P:negative regulation of Wnt signaling pathway; ISS:UniProtKB.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IDA:UniProtKB.
DR   GO; GO:0010468; P:regulation of gene expression; IBA:GO_Central.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0033136; P:serine phosphorylation of STAT3 protein; ISS:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007223; P:Wnt signaling pathway, calcium modulating pathway; TAS:Reactome.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR003527; MAP_kinase_CS.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01351; MAPK; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Complete proteome; Cytoplasm; Kinase; Magnesium;
KW   Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Transcription; Transcription regulation; Transferase;
KW   Wnt signaling pathway.
FT   CHAIN         1    527       Serine/threonine-protein kinase NLK.
FT                                /FTId=PRO_0000186336.
FT   DOMAIN      138    427       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     144    152       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION        1    304       Required for interaction with TAB2.
FT                                {ECO:0000250}.
FT   REGION        1    125       Sufficient for interaction with DAPK3.
FT                                {ECO:0000269|PubMed:21454679}.
FT   REGION      124    416       Sufficient for interaction with DAPK3.
FT                                {ECO:0000269|PubMed:21454679}.
FT   REGION      428    527       Required for homodimerization and kinase
FT                                activation and localization to the
FT                                nucleus. {ECO:0000250}.
FT   REGION      434    527       Required for interaction with TAB2.
FT                                {ECO:0000250}.
FT   MOTIF       298    300       TQE.
FT   COMPBIAS     22     25       Poly-Ala.
FT   COMPBIAS     27     34       Poly-His.
FT   COMPBIAS     42     48       Poly-His.
FT   COMPBIAS     71     83       Poly-Ala.
FT   COMPBIAS    106    111       Poly-Ala.
FT   COMPBIAS    115    119       Poly-Ala.
FT   ACT_SITE    264    264       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     167    167       ATP. {ECO:0000305}.
FT   MOD_RES     298    298       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     522    522       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   VARIANT     177    177       V -> A (in dbSNP:rs11871287).
FT                                /FTId=VAR_019549.
FT   VARIANT     343    343       A -> T (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042273.
FT   MUTAGEN     167    167       K->N: Abrogates kinase activity.
FT                                {ECO:0000269|PubMed:17952062,
FT                                ECO:0000269|PubMed:20061393}.
FT   CONFLICT     25     25       A -> T (in Ref. 5; AAH64663).
FT                                {ECO:0000305}.
SQ   SEQUENCE   527 AA;  58283 MW;  CE6AEBA7D8133989 CRC64;
     MSLCGARANA KMMAAYNGGT SAAAAGHHHH HHHHLPHLPP PHLHHHHHPQ HHLHPGSAAA
     VHPVQQHTSS AAAAAAAAAA AAAMLNPGQQ QPYFPSPAPG QAPGPAAAAP AQVQAAAAAT
     VKAHHHQHSH HPQQQLDIEP DRPIGYGAFG VVWSVTDPRD GKRVALKKMP NVFQNLVSCK
     RVFRELKMLC FFKHDNVLSA LDILQPPHID YFEEIYVVTE LMQSDLHKII VSPQPLSSDH
     VKVFLYQILR GLKYLHSAGI LHRDIKPGNL LVNSNCVLKI CDFGLARVEE LDESRHMTQE
     VVTQYYRAPE ILMGSRHYSN AIDIWSVGCI FAELLGRRIL FQAQSPIQQL DLITDLLGTP
     SLEAMRTACE GAKAHILRGP HKQPSLPVLY TLSSQATHEA VHLLCRMLVF DPSKRISAKD
     ALAHPYLDEG RLRYHTCMCK CCFSTSTGRV YTSDFEPVTN PKFDDTFEKN LSSVRQVKEI
     IHQFILEQQK GNRVPLCINP QSAAFKSFIS STVAQPSEMP PSPLVWE
//
